| 2017 | | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | 박준성, 정성현 |
| 2022 | | BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis | 노진, 정성현, 최윤석 |
| 1997 | | Bilateral primary renal non-Hodgkin's lymphoma presenting with acute renal failure: successful treatment with systemic chemotherapy. | 최진혁 |
| 1996 | | Concurrent presentation of erythrocytic and megakaryocytic aplasia. | 김효철 |
| 2016 | | Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study | 신성재 |
| 2016 | | High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy | 강석윤, 김장희, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁, 한재호 |
| 2019 | | Impaired endothelial function may predict treatment response in restless legs syndrome | 박동규, 윤정한 |
| 2019 | | Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death | 최경숙, 최용원 |
| 2017 | | Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study | 박준은 |
| 2014 | | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2022 | | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | 정성현, 최윤석 |
| 2019 | | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 정성현 |
| 2015 | | Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. | 고영화 |
| 2012 | | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | 정성현 |
| 2020 | | Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | 노진, 박준성, 정성현, 한재호 |
| 1994 | | Serum erythropoietin levels after living-donor renal allografts. | 김흥수 |
